Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016

K. Hemminki, A. Försti, M. Hansson

. 2021 ; 11 (1) : 17272. [pub] 20210826

Language English Country Great Britain

Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22003894

Survival in multiple myeloma (MM) has developed favorably over the past decades for reasons that have been ascribed to new medications and treatment. However, development of survival over a long period and comparison to other hematopoietic neoplasms (HN) is less well known. Here we used Swedish cancer data from the Nordcan database, spanning a 50-year period from 1967 to 2016, and analyzed 1- and 5-year survival data. As a novel type of analysis we calculate the difference in survival between year 1 and 5 which indicates how well survival was maintained in the 4-year period following year 1 after diagnosis. The relative 1- and 5- year survival increased constantly; the 5-year survival graph for women was almost linear. The difference between 1- and 5-year survival revealed that the 5-year survival gain was entirely due to the improvement in 1-year survival, except for the last period. Survival improvement in all HNs exceeded that in MM. The linear 5-year survival increase for female MM patients suggests a contribution by many small improvements in the first year care rather than single major events. The future challenges are to push the gains past year 1 and to extend them to old patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003894
003      
CZ-PrNML
005      
20220127145742.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-021-96804-8 $2 doi
035    __
$a (PubMed)34446811
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Hemminki, Kari $u Faculty of Medicine and Biomedical Center in Pilsen, Biomedical Center, Charles University in Prague, 30605, Pilsen, Czech Republic. K.Hemminki@dkfz.de $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120, Heidelberg, Germany. K.Hemminki@dkfz.de
245    10
$a Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016 / $c K. Hemminki, A. Försti, M. Hansson
520    9_
$a Survival in multiple myeloma (MM) has developed favorably over the past decades for reasons that have been ascribed to new medications and treatment. However, development of survival over a long period and comparison to other hematopoietic neoplasms (HN) is less well known. Here we used Swedish cancer data from the Nordcan database, spanning a 50-year period from 1967 to 2016, and analyzed 1- and 5-year survival data. As a novel type of analysis we calculate the difference in survival between year 1 and 5 which indicates how well survival was maintained in the 4-year period following year 1 after diagnosis. The relative 1- and 5- year survival increased constantly; the 5-year survival graph for women was almost linear. The difference between 1- and 5-year survival revealed that the 5-year survival gain was entirely due to the improvement in 1-year survival, except for the last period. Survival improvement in all HNs exceeded that in MM. The linear 5-year survival increase for female MM patients suggests a contribution by many small improvements in the first year care rather than single major events. The future challenges are to push the gains past year 1 and to extend them to old patients.
650    _2
$a senioři $7 D000368
650    _2
$a databáze faktografické $x statistika a číselné údaje $7 D016208
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a hematologické nádory $x diagnóza $x mortalita $x terapie $7 D019337
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mortalita $x trendy $7 D009026
650    _2
$a mnohočetný myelom $x diagnóza $x mortalita $x terapie $7 D009101
650    _2
$a registrace $x statistika a číselné údaje $7 D012042
650    _2
$a míra přežití $7 D015996
651    _2
$a Švédsko $x epidemiologie $7 D013548
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany
700    1_
$a Hansson, Markus $u Sahlgrenska Academy, 413 25, Göteborg, Sweden $u Sahlgrenska University Hospital, 413 25, Göteborg, Sweden
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 11, č. 1 (2021), s. 17272
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34446811 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145738 $b ABA008
999    __
$a ok $b bmc $g 1751378 $s 1155043
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 1 $d 17272 $e 20210826 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Archiving options